IMMURON LTD-SPON ADR (IMRN)
US45254U1016 - ADR
Taking everything into account, IMRN scores 3 out of 10 in our fundamental rating. IMRN was compared to 568 industry peers in the Biotechnology industry. IMRN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. IMRN is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year IMRN has reported negative net income.
In the past year IMRN has reported a negative cash flow from operations.
IMRN had negative earnings in each of the past 5 years.
IMRN had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
IMRN's Return On Assets of -44.61% is in line compared to the rest of the industry. IMRN outperforms 51.86% of its industry peers.
The Return On Equity of IMRN (-54.58%) is better than 64.25% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -44.61% | ||
| ROE | -54.58% | ||
| ROIC | N/A |
ROA(3y)-24.44%
ROA(5y)-30.3%
ROE(3y)-28.73%
ROE(5y)-34.09%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
IMRN has a Gross Margin of 68.06%. This is amongst the best in the industry. IMRN outperforms 82.12% of its industry peers.
IMRN's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for IMRN so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 68.06% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.56%
GM growth 5Y-1.13%
2. Health
2.1 Basic Checks
IMRN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for IMRN remains at a similar level compared to 1 year ago.
IMRN has more shares outstanding than it did 5 years ago.
The debt/assets ratio for IMRN is higher compared to a year ago.
2.2 Solvency
IMRN has an Altman-Z score of -2.84. This is a bad value and indicates that IMRN is not financially healthy and even has some risk of bankruptcy.
IMRN has a Altman-Z score (-2.84) which is in line with its industry peers.
IMRN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -2.84 |
ROIC/WACCN/A
WACC11.6%
2.3 Liquidity
A Current Ratio of 5.46 indicates that IMRN has no problem at all paying its short term obligations.
IMRN has a Current ratio (5.46) which is comparable to the rest of the industry.
A Quick Ratio of 4.87 indicates that IMRN has no problem at all paying its short term obligations.
IMRN has a Quick ratio of 4.87. This is comparable to the rest of the industry: IMRN outperforms 55.04% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.46 | ||
| Quick Ratio | 4.87 |
3. Growth
3.1 Past
The earnings per share for IMRN have decreased strongly by -83.15% in the last year.
The Revenue has grown by 171.67% in the past year. This is a very strong growth!
The Revenue has been growing by 15.48% on average over the past years. This is quite good.
EPS 1Y (TTM)-83.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-168.77%
Revenue 1Y (TTM)171.67%
Revenue growth 3Y222.79%
Revenue growth 5Y15.48%
Sales Q2Q%108.61%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
IMRN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
IMRN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
IMMURON LTD-SPON ADR
NASDAQ:IMRN (12/20/2024, 8:18:26 PM)
1.96
-0.04 (-1.75%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst OwnersN/A
Inst Owner Change-6.07%
Ins Owners7.77%
Ins Owner ChangeN/A
Market Cap11.17M
Analysts0
Price TargetN/A
Short Float %0%
Short Ratio0.85
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 3.65 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.41 | ||
| P/tB | 1.41 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.76
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.64
FCFYN/A
OCF(TTM)-0.64
OCFYN/A
SpS0.54
BVpS1.39
TBVpS1.39
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -44.61% | ||
| ROE | -54.58% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 68.06% | ||
| FCFM | N/A |
ROA(3y)-24.44%
ROA(5y)-30.3%
ROE(3y)-28.73%
ROE(5y)-34.09%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.56%
GM growth 5Y-1.13%
F-Score3
Asset Turnover0.32
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | 0% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 5.46 | ||
| Quick Ratio | 4.87 | ||
| Altman-Z | -2.84 |
F-Score3
WACC11.6%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)0.58%
Cap/Sales(5y)1.27%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-83.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-168.77%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)171.67%
Revenue growth 3Y222.79%
Revenue growth 5Y15.48%
Sales Q2Q%108.61%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-53.01%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-125.91%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-126.58%
OCF growth 3YN/A
OCF growth 5YN/A